FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

21 Apr 15

Cancer Genetics Expands Next-Generation Sequencing Capabilities in India Through Launch of Solid Tumor Hotspot Panel for Biopharma and Clinical Customers Throughout Asia (read more...)

- > Over 370,000 patients in India develop solid tumor based cancers annually and are in need of more comprehensive genomic profiling > The (read more...)
16 Apr 15

Cancer Genetics, Inc. Receives New York State Licensure for FHACT(R) Cervical Cancer Test (read more...)

- RUTHERFORD, N.J., April 16, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-(read more...)

Events

14 May 15

Annual Meeting of Stockholders

- The meeting will be held at the offices of the Company, located at 201 Route 17 North, 2nd Floor, Rutherford, New Jersey 07070. Proxy Statement(read more...)
05 May 15

International Society for Biological and Environmental Repositories

21 Mar 15

United States & Canadian Academy of Pathology

Clinicians
Patients